Physician profile
Gary H Silber
NPI 1932169364
$4,410.99
in general payments reported to CMS, 2019-2025
9 companies · $317 in 2025
The $317 reported for 2025 was more than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $3,120 · 2021: $156 · 2022: $381 · 2023: $139 · 2024: $118 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $573.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $3,543.64 | 2020-2025 | Gattex |
| Abbvie INC. | $376.42 | 2019-2025 | |
| Genzyme Corporation | $180.78 | 2023-2025 | |
| Alcresta Therapeutics, INC. | $132.45 | 2019-2025 | Relizorb |
| Janssen Scientific Affairs, LLC | $116.91 | 2022 | |
| Shire North American Group INC | $33.54 | 2019 | |
| Qol Medical, LLC | $19.38 | 2021 | |
| Travere Therapeutics, INC. | $7.87 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Silber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.